Nordic Pharma, a subsidiary of SEVER Life Sciences, showcased LACRIFILL Canalicular Gel at the American Academy of Ophthalmology Annual Meeting 2026. The gel, used by over 2,200 US eye care practices and more than 130,000 patients, helps manage symptoms after cataract or refractive surgery and dry eye disease. Recent surveys show 96% of cataract surgery patients and 91% overall report improved eye comfort. This therapy reduces reliance on eye drops and supports better postoperative recovery and vision stability. Nordic Pharma will demonstrate the gel at their booth and share further data with attendees.
SEVER Life Sciences' subsidiary Nordic Pharma's LACRIFILL Canalicular Gel is highlighted alongside Pluang's health sector data. For readers following health stocks, here is Pluang's market snapshot as of Oct 07, 2026 21:21 WIB: out of 100 priced US health stocks, 56 rose and 43 fell. Notable movers include TMDX at USD 83.06 with a 3.46% increase and 100% buy order activity, SANA at USD 2.83 up 2.91% with 94% buy orders, and CVS at USD 88.77 rising 2.70% but with 100% sell orders.
BNP Paribas lowered Hormel Foods' price target from $26 to $23, indicating a potential 16.2% upside from its current price of around $19.80. Despite a 50.5% decline in its share price over five years, Hormel Foods remains attractive for dividend inve...
Barclays initiated coverage of Becton, Dickinson and Company (BDX) with an "Underweight" rating, indicating a cautious outlook for the medical technology stock. BDX is partnering with the U.S. government to boost domestic manufacturing and strengthen...
Morgan Stanley increased its price target for Eli Lilly to $1,430 from $1,419, maintaining an Overweight rating. This new target implies a potential upside of about 20.8% from the current share price of around $1,184. The adjustment reflects updated ...
Arthur J. Gallagher expects about 6% organic growth in Q3, driven by strong client retention and new business despite easing property insurance pricing. Cantor Fitzgerald lowered its price target to $280, below the $288 average from 19 analysts who m...
Needham raised Zscaler's price target to $255, citing strong demand for AI-related cybersecurity solutions. Zscaler aims to exceed $8 billion in annual recurring revenue by fiscal 2031, driven by increasing needs to protect against AI-powered cyberat...
